Literature DB >> 22259133

MUC1 membrane trafficking: protocols for assessing biosynthetic delivery, endocytosis, recycling, and release through exosomes.

Franz-Georg Hanisch1, Carol L Kinlough, Simon Staubach, Rebecca P Hughey.   

Abstract

MUC1 is normally apical in polarized epithelial cells but is aberrantly localized in tumor cells. To better understand the mechanism of this altered localization as well as the normal functions of MUC1, we are focused on characterizing the features of MUC1 that regulate the membrane trafficking of this mucin-like transmembrane protein. Previous studies using heterologous expression of MUC1 in CHO and MDCK cells revealed that trafficking to the cell surface as well as endocytosis and recycling is modulated by glycosylation, palmitoylation, and docking of adaptor protein complexes. Protocols for assessing MUC1 trafficking have utilized membrane-impermeant cell surface biotinylation and subsequent stripping with reducing reagents, such as MESNA. The cumulative data have been used for computer modeling and calculation of rate constants. As MUC1 is released through trafficking to exosomes, we have devised protocols for the affinity isolation of MUC1-containing lipid rafts from nanovesicular subpopulations to perform proteomic mapping of protein constituents in these sorting platforms. Our studies to date have shown that plasma membranous MUC1 traffics via lipid raft-associated pathways to exosomes, which are independent of caveolin-1 or dynamin, but dependent on flotillin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22259133     DOI: 10.1007/978-1-61779-513-8_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  5 in total

Review 1.  MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment.

Authors:  Donald W Kufe
Journal:  Carcinogenesis       Date:  2020-09-24       Impact factor: 4.944

2.  Sialylation of MUC4β N-glycans by ST6GAL1 orchestrates human airway epithelial cell differentiation associated with type-2 inflammation.

Authors:  Xiuxia Zhou; Carol L Kinlough; Rebecca P Hughey; Mingzhu Jin; Hideki Inoue; Emily Etling; Brian D Modena; Naftali Kaminski; Eugene R Bleecker; Deborah A Meyers; Nizar N Jarjour; John B Trudeau; Fernando Holguin; Anuradha Ray; Sally E Wenzel
Journal:  JCI Insight       Date:  2019-03-07

3.  Evidence for core 2 to core 1 O-glycan remodeling during the recycling of MUC1.

Authors:  Hanieh Razawi; Carol L Kinlough; Simon Staubach; Paul A Poland; Youssef Rbaibi; Ora A Weisz; Rebecca P Hughey; Franz-Georg Hanisch
Journal:  Glycobiology       Date:  2013-05-01       Impact factor: 4.313

Review 4.  Emergence of MUC1 in Mammals for Adaptation of Barrier Epithelia.

Authors:  Donald W Kufe
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

5.  Plasma Mucin-1 (CA15-3) Levels in Autosomal Dominant Tubulointerstitial Kidney Disease due to MUC1 Mutations.

Authors:  Petr Vylet'al; Kendrah Kidd; Hannah C Ainsworth; Drahomíra Springer; Alena Vrbacká; Anna Přistoupilová; Rebecca P Hughey; Seth L Alper; Niall Lennon; Steven Harrison; Maegan Harden; Victoria Robins; Abbigail Taylor; Lauren Martin; Katrice Howard; Ibrahim Bitar; Carl D Langefeld; Veronika Barešová; Hana Hartmannová; Kateřina Hodaňová; Tomáš Zima; Martina Živná; Stanislav Kmoch; Anthony J Bleyer
Journal:  Am J Nephrol       Date:  2021-06-07       Impact factor: 3.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.